PFIZER INC Equity Securities, FV-NI, Gain (Loss)
PFIZER INC (PFE) reported Equity Securities, FV-NI, Gain (Loss) of -$37.00 million for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2026-08-04
- PFIZER INC equity securities, fv-ni, gain (loss) for the quarter ending 2026-06-28 was -$37.00M, a 149.33% decline year-over-year.
- PFIZER INC equity securities, fv-ni, gain (loss) for the quarter ending 2026-03-29 was -$9.00M.
- PFIZER INC equity securities, fv-ni, gain (loss) for the quarter ending 2025-12-31 was $27.00M, a 96.93% decline year-over-year.
- PFIZER INC equity securities, fv-ni, gain (loss) for the quarter ending 2025-09-28 was $201.00M, a 54.93% decline year-over-year.
- PFIZER INC equity securities, fv-ni, gain (loss) for fiscal 2025 was -$67.00M, a 106.65% decline from fiscal 2024.
- PFIZER INC equity securities, fv-ni, gain (loss) for fiscal 2024 was $1.01B, a 36.60% decline from fiscal 2023.
- PFIZER INC equity securities, fv-ni, gain (loss) for fiscal 2023 was $1.59B.
- PFIZER INC equity securities, fv-ni, gain (loss) for fiscal 2022 was -$1.27B, a 194.72% decline from fiscal 2021.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 6 month as first filed | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-28 | -$37.00M 10-Q · filed 2026-08-04 | -$46.00M 10-Q · filed 2026-08-04 | -$19.00M derived: sum of 3 quarters · filed 2026-08-04 | $182.00M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2026-03-29 | -$9.00M 10-Q · filed 2026-05-05 | $18.00M derived: sum of 2 quarters · filed 2026-05-05 | $219.00M derived: sum of 3 quarters · filed 2026-05-05 | $294.00M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-12-31 | $27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $228.00M derived: sum of 2 quarters · filed 2026-02-26 | $303.00M derived: sum of 3 quarters · filed 2026-08-04 | -$67.00M 10-K · filed 2026-02-26 | ||
| 2025-09-28 | $201.00M 10-Q · filed 2025-11-04 | $276.00M derived: sum of 2 quarters · filed 2026-08-04 | -$94.00M 10-Q · filed 2025-11-04 | $785.00M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-06-29 | $75.00M 10-Q · filed 2026-08-04 | -$295.00M 10-Q · filed 2026-08-04 | $584.00M derived: sum of 3 quarters · filed 2026-08-04 | $1.03B derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-03-30 | -$370.00M 10-Q · filed 2026-05-05 | $509.00M derived: sum of 2 quarters · filed 2026-05-05 | $955.00M derived: sum of 3 quarters · filed 2026-05-05 | $613.00M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | $879.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.32B derived: sum of 2 quarters · filed 2026-02-26 | $983.00M derived: sum of 3 quarters · filed 2026-02-26 | $1.01B 10-K · filed 2026-02-26 | ||
| 2024-09-29 | $446.00M 10-Q · filed 2025-11-04 | $104.00M derived: sum of 2 quarters · filed 2025-11-04 | $129.00M 10-Q · filed 2025-11-04 | $2.43B derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | -$342.00M 10-Q · filed 2025-08-05 | -$317.00M 10-Q · filed 2025-08-05 | $1.98B derived: sum of 3 quarters · filed 2026-02-26 | $1.59B derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $25.00M 10-Q · filed 2025-05-05 | $2.32B derived: sum of 2 quarters · filed 2026-02-26 | $1.93B derived: sum of 3 quarters · filed 2026-02-26 | $2.07B derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $2.30B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.91B derived: sum of 2 quarters · filed 2026-02-26 | $2.04B derived: sum of 3 quarters · filed 2026-02-26 | $1.59B 10-K · filed 2026-02-26 | ||
| 2023-10-01 | -$393.00M 10-Q · filed 2024-11-04 | -$258.00M derived: sum of 2 quarters · filed 2024-11-04 | -$709.00M 10-Q · filed 2024-11-04 | -$629.00M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-07-02 | $135.00M 10-Q · filed 2024-08-05 | -$316.00M 10-Q · filed 2024-08-05 | -$236.00M derived: sum of 3 quarters · filed 2025-02-27 | -$348.00M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-04-02 | -$451.00M 10-Q · filed 2024-05-08 | -$371.00M derived: sum of 2 quarters · filed 2025-02-27 | -$483.00M derived: sum of 3 quarters · filed 2025-02-27 | -$1.02B derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | $80.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$32.00M derived: sum of 2 quarters · filed 2025-02-27 | -$573.00M derived: sum of 3 quarters · filed 2025-02-27 | -$1.27B 10-K · filed 2025-02-27 | ||
| 2022-10-02 | -$112.00M 10-Q · filed 2023-11-08 | -$653.00M derived: sum of 2 quarters · filed 2023-11-08 | -$1.35B 10-Q · filed 2023-11-08 | -$1.61B derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-07-03 | -$541.00M 10-Q · filed 2023-08-09 | -$1.24B 10-Q · filed 2023-08-09 | -$1.50B derived: sum of 3 quarters · filed 2024-02-22 | -$1.10B derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-04-03 | -$699.00M 10-Q · filed 2023-05-10 | -$956.00M derived: sum of 2 quarters · filed 2024-02-22 | -$556.00M derived: sum of 3 quarters · filed 2024-02-22 | $244.00M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2021-12-31 | -$257.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $143.00M derived: sum of 2 quarters · filed 2024-02-22 | $943.00M derived: sum of 3 quarters · filed 2024-02-22 | $1.34B 10-K · filed 2024-02-22 | ||
| 2021-10-03 | $400.00M 10-Q · filed 2022-11-09 | $1.20B derived: sum of 2 quarters · filed 2022-11-09 | $1.60B 10-Q · filed 2022-11-09 | $1.73B derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-07-04 | $800.00M 10-Q · filed 2022-08-10 | $1.20B 10-Q · filed 2022-08-10 | $1.33B derived: sum of 3 quarters · filed 2023-02-23 | $1.26B derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-04-04 | $401.00M 10-Q · filed 2022-05-11 | $533.00M derived: sum of 2 quarters · filed 2023-02-23 | $463.00M derived: sum of 3 quarters · filed 2023-02-23 | $1.20B derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2020-12-31 | $132.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $62.00M derived: sum of 2 quarters · filed 2023-02-23 | $794.00M derived: sum of 3 quarters · filed 2023-02-23 | $540.00M 10-K · filed 2023-02-23 | ||
| 2020-09-27 | -$70.00M 10-Q · filed 2021-11-12 | $662.00M derived: sum of 2 quarters · filed 2021-11-12 | $408.00M 10-Q · filed 2021-11-12 | $708.00M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-06-28 | $732.00M 10-Q · filed 2021-08-12 | $478.00M 10-Q · filed 2021-08-12 | $778.00M derived: sum of 3 quarters · filed 2022-02-24 | $784.00M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-03-29 | -$255.00M 10-Q · filed 2021-05-13 | $46.00M derived: sum of 2 quarters · filed 2022-02-24 | $52.00M derived: sum of 3 quarters · filed 2022-02-24 | $88.00M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $301.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $307.00M derived: sum of 2 quarters · filed 2022-02-24 | $343.00M derived: sum of 3 quarters · filed 2022-02-24 | $454.00M 10-K · filed 2022-02-24 | ||
| 2019-09-29 | $6.00M 10-Q · filed 2020-11-05 | $42.00M derived: sum of 2 quarters · filed 2020-11-05 | $153.00M 10-Q · filed 2020-11-05 | $279.00M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-06-30 | $36.00M 10-Q · filed 2020-08-06 | $147.00M 10-Q · filed 2020-08-06 | $273.00M derived: sum of 3 quarters · filed 2021-02-25 | $358.00M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-03-31 | $111.00M 10-Q · filed 2020-05-07 | $237.00M derived: sum of 2 quarters · filed 2021-02-25 | $322.00M derived: sum of 3 quarters · filed 2021-02-25 | $579.00M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $126.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $211.00M derived: sum of 2 quarters · filed 2021-02-25 | $468.00M derived: sum of 3 quarters · filed 2021-02-25 | $586.00M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $85.00M 10-Q · filed 2019-11-07 | $94.00M 10-Q · filed 2018-11-08 | $342.00M derived: sum of 2 quarters · filed 2019-11-07 | $460.00M 10-Q · filed 2019-11-07 | $573.00M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-07-01 | $257.00M 10-Q · filed 2019-08-08 | $232.00M 10-Q · filed 2018-08-09 | $375.00M 10-Q · filed 2019-08-08 | $330.00M 10-Q · filed 2018-08-09 | $488.00M derived: sum of 3 quarters · filed 2020-02-27 | $533.00M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-04-01 | $118.00M 10-Q · filed 2019-05-09 | $231.00M derived: sum of 2 quarters · filed 2020-02-27 | $276.00M derived: sum of 3 quarters · filed 2020-02-27 | |||
| 2017-12-31 | $113.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $158.00M derived: sum of 2 quarters · filed 2020-02-27 | $224.00M 10-K · filed 2020-02-27 | |||
| 2017-10-01 | $45.00M 10-Q · filed 2018-11-08 | $111.00M 10-Q · filed 2018-11-08 | ||||
| 2016-12-31 | $18.00M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |